Byrski and colleagues present the results of a prospective phase II study of cisplatin in BRCA1-related metastatic breast cancer -that is, breast cancer arising in women with a germline mutation in BRCA1 [1] . Th ey report evidence of substantial effi cacy with an overall response rate of 80%, including 45% with complete response, and a time to progression of 12 months. Th e majority of patients in the study had triple receptor-negative breast cancer, and this time to progression compares favorably with median progression-free survival for triple receptornegative breast cancer in contemporary series [2] . Th is study follows on from a retrospective study by the same group that reported a pathological complete response rate of 83% with neoadjuvant cisplatin chemotherapy, compared with a rate of 15% with nonrandomized comparator neo adjuvant chemotherapy [3] .
that can only be adequately repaired by HR-based DNA repair, and consequently BRCA1-defi cient and BRCA2-defi cient cells are highly sensitive to platinum chemotherapy both in vitro and in vivo. With high response rates in a pros pective clinical trial, and a strong biological rationale, it is time to ask whether we are moving towards a new chemo therapy standard for BRCA1-related, and poten tially by inference BRCA2-related, breast cancer or whether we need more evidence.
Th e main strength of the current study is that it has been carried out at all. BRCA1 mutations account for a small proportion of patients with advanced breast cancer, even in countries with founder mutations, and this presents a substantial barrier to running studies testing standard chemotherapy. Use of the chemotherapy regimen outside the trial, and the wide availability of novel therapy trials competing for the same patients, add to the challenges of recruiting such trials. Nevertheless, the study by Byrski and colleagues is an open-label singlearm study of only 20 patients, with no central radiological confi rmation of response rates, and both this study design and this size make a meaningful interpretation of progression-free survival very diffi cult. Th e study was in addition not prospectively registered in a clinical trial registry, removing one of the safeguards against publication bias.
Th e study is dominated by women with three specifi c mutations in BRCA1 that represent the three founder mutations found in the Polish population [1] , with over one-half being the single mutation 5382insC. One of these mutations, C61G, is predicted not to sensitize to cisplatin on the basis of preclinical data [6] yet cancers with this mutation appear to be just as sensitive to cisplatin in the study [1] , a discrepancy for which it is important to under stand the basis. Prior studies reported by this group have also been drawn from the Polish founder mutations, and we have limited data on the response of cancers with other BRCA1 mutations, and very limited data for BRCA2 mutations.
Although the data for BRCA1/2-related breast are therefore relatively limited, there are substantial data on the sensitivity of BRCA1-related and BRCA2-related Abstract A recent prospective clinical trial provides further evidence that breast cancers arising in germline BRCA1 mutation carriers are highly sensitive to cisplatin chemotherapy. The potential signifi cance of these data for the management of patients with BRCA1-related and BRCA2-related breast cancer is discussed. ovarian cancers to platinum-based chemotherapy [7, 8] . BRCA1/2-related serous ovarian cancers are highly sensitive to platinum chemotherapy, and remain sensitive to repeat challenges with platinum chemotherapy, which likely explains the improved survival of BRCA1/2-related serous ovarian cancer compared with BRCA1/2 wildtype serous ovarian cancer [8] .
Should the accumulation of data, which includes this study by Byrski and colleagues, alter our approach to the treatment of BRCA1-related and BRCA2-related breast cancer? For patients with metastatic BRCA1-related breast cancer, although the data are limited, it seems clear that these patients should be off ered the option of platinum-contain ing chemotherapy at some point during their treat ment course. Whether platinum chemotherapy should be used as the fi rst line in preference to other chemotherapy agents is unclear, and this is the subject of the BRCA trial (NCT00321633, NCT00532727) that randomizes fi rst-line patients between carboplatin and docetaxel. For those with BRCA1 mutation-associated triple receptor-negative breast cancer and anthracyclineresistant and taxane-resistant disease, where there are few available active therapies, and the option of platinumagent chemotherapy seems well founded.
Whether the platinum agent should be cisplatin or whether carboplatin would have a similar response rate is unknown. Any diff erence in effi cacy between the two drugs is likely to be small and may be outweighed by logistical and toxicity advantages for the patient. Whether patients with evidence of disease response and a long platinum-free interval (>6 months off chemotherapy) should be retreated with platinum-based chemo therapy on progression or whether they should be treated with alternative chemotherapy regimens remains unclear, and we await data to guide such decisions. Although there are few direct data on BRCA2-related breast cancer, the strength of the biological rational, the comparative data between BRCA1 and BRCA2 in ovarian cancer, and the evidence of poly(ADP ribose) polymerase (PARP) inhibitor effi cacy in BRCA2-related breast cancer [9] all suggest that similar advice should apply to BRCA2-related breast cancer.
What about the curative setting and patients receiving adjuvant or neoadjuvant chemotherapy? Here the data are less robust. Standard adjuvant anthracycline/taxane chemotherapy cures a substantial proportion of women with breast cancer, with evidence of better outcomes and therapy responses in the BRCA1/2 carrier population [10, 11] , so changes to this standard should only be made on the basis of strong evidence. At present the data to support platinum agents in this context are limited to retrospective analysis [3] or to prospective data for a very small number of patients [12] . Prospective studies are still required before routine practice changes in the curative setting. Th e one current exception to this is in the treatment of HER2-positive breast cancer in BRCA1/2 carriers. Relative equipoise has already been shown in the general breast cancer population for the TCH (docetaxel, carbo platin, trastuzumab) regimen compared with standard anthracycline-taxane-trastuzumab-based chemotherapy [13] , and the TCH (docetaxel, carboplatin, trastu zumab) regimen presents an attractive option for BRCA1/2 carriers with HER2-positive breast cancer.
PARP inhibitors target the same HR-based DNA repair defect as cisplatin chemotherapy, and there is evidence of effi cacy for the PARP inhibitor olaparib in BRCA1-related and BRCA2-related breast cancer with substantial prior chemotherapy exposure [9] . PARP inhibitors target the DNA repair defect in a more specifi c fashion and are well tolerated without typical chemotherapy side eff ects [9] . Th e challenge in BRCA1/2-related advanced breast cancer is to develop and support a collaborative mechanism where patients can be identifi ed and entered into randomized trials that test novel therapies such as PARP inhibitors, or mechanistically based chemotherapy, to robustly assess the effi cacy relative to standard care, and therefore allow these patients to benefi t from these BRCA1/2-focused treatments.
